Aimovig was specifically developed to prevent migraine by blocking the CGRP-R, which is associated with migraine.
Studied in several large global, randomized, double-blind, placebo-controlled studies to assess its efficacy and safety in migraine prevention, more than 3,000 patients have participated in the Aimovig clinical program across four placebo-controlled Phase 2 and Phase 3 clinical studies and their open-label extensions.
Aimovig was consistently shown to reduce monthly migraine days, including in more difficult-to-treat populations, with many patients achieving at least a 50% reduction of monthly migraine days from baseline over the last four weeks of the double-blind treatment phase of the study.
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide.
It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007